The FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent endometrial cancer that is mismatch repair-deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).
Efficacy was evaluated in RUBY, a multicenter, randomized, double-blind, placebo-controlled trial. Efficacy was assessed in a pre-specified subgroup of 122 patients with dMMR/MSI-H
AUGUST 2, 2023